-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

Benzinga·09/08/2026 14:13:34
语音播报
TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.